Clinical Trial Update: TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating TQB2930 Injection for HER2-positive advanced breast cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• TQB2930

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Conditions: HER2-positive Advanced Breast Cancer | Phase 3 | Status: RECRUITING